This site is intended for Great Britain healthcare professionals only 
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

PATIENT PROFILE 4

Teenage competitive swimmer suffering with regular disease flares and itching​​​​​​​​​​​​​​


Who is the patient?

This patient profile is fictional and has been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.​​​​​​​
  • ​​​​​​​Anglo-Chinese female, 14 years old
  • Disease and treatment history: Diagnosis of AD at age 12; prone to seasonal flares that are particularly itchy. Various approved treatments tried but lesions continue to worsen; treatments included topical corticosteroids for flare management, TCI (pimecrolimus 1% BID) and phototherapy
  • Clinical assessment: EASI=24; 40% BSA (primarily the torso and legs)
  • Personal impact: A competitive swimmer who trains daily (which may exacerbate her flares), she is very conscious of her lesions and is considering giving up the sport due to appearance-related bullying
  • Preferences: Severely needle-phobic, but her parents have indicated they could manage injections if absolutely necessary
​​​​​​​

Why consider Cibinqo (abrocitinib)?

1. Significantly more patients achieved skin clearance at Week 12 with Cibinqo vs placebo1–3

JADE TEEN (CO-PRIMARY ENDPOINTS, IN COMBINATION WITH MEDICATED TOPICAL THERAPY)

Proportion of patients achieving IGA 0/1 at Week 12

IGA 0/1 at Week 12

no./Total no. (%, 95% CI)

Cibinqo 200 mg

43/93 (46.2%; 36.1–56.4)

Cibinqo 100 mg

37/89 (41.6%; 31.3–51.8)

Placebo

23/94 (24.5%; 15.8–33.2)

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily. 

​​​​​​​

Proportion of patients achieving EASI-75

EASI-75 at Week 12

no./Total no. (%, 95% CI)

Cibinqo 200 mg

67/93 (72.0%; 62.9–81.2)

Cibinqo 100 mg

61/89 (68.5%; 58.9–78.2)

Placebo

39/94 (41.5%; 31.5–51.4)

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily. 

​​​​​​​

2. Significantly more patients achieved itch relief with Cibinqo vs placebo1–3

JADE TEEN (KEY SECONDARY ENDPOINT, IN COMBINATION WITH MEDICATED TOPICAL THERAPY)

Proportion of patients achieving PP-NRS4

PP-NRS4 at Week 12

n0./Total no. (%, 95% CI)

Cibinqo 200 mg

41/74 (55.4%; 44.1–66.7)

Cibinqo 100 mg

40/76 (52.6%; 41.4–63.9)

Placebo

25/84 (29.8%; 20.0–39.5)

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily. 

​​​​​​​

3. Cibinqo helps reduce flares vs placebo*1,4

JADE REGIMEN (PRIMARY ENDPOINT)

Cumulative probability of patients experiencing a flare

Explore more

Patient 1

Unemployed male with increasingly uncontrolled itching leading to sleep deprivation, weight gain and low self-esteem.

View profile

Patient 2

Middle-aged mother with uncontrolled, severe eczematous lesions, resulting in selfconsciousness and anxiety.

View profile

This patient profile is fictional and has been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.​​​​​​​

*Flare defined as losing the IGA response (IGA ≥2) AND losing at least 50% of the EASI response obtained at Week 12 of the open-label induction phase. Following an open-label run-in period of 12 weeks in which patients received Cibinqo 200 mg OD, responders were randomised 1:1:1 to receive either Cibinqo 200 mg, Cibinqo 100 mg, or placebo.
This study included a 12-week induction period.

AD=atopic dermatitis; BID=twice daily; BSA=body surface area; CI​​​​​​​=confidence interval; EASI=Eczema Area and Severity Index; HR=hazard ratio; IGA=Investigator’s Global Assessment; LSM=least squares mean; NS=not significant; OD=once daily; OL=open label; PP-NRS=Peak Pruritus Numerical Rating Scale.
References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics. 2. Eichenfield L, et al. JAMA Dermatol 2021;doi:10.1001/jamadermatol.2021.2830. 3. Eichenfield L, et al. JAMA Dermatol 2021;doi:10.1001/jamadermatol.2021.2830. Supplementary appendix 3. 4. Blauvelt A, et al. JAAD 2021; doi.org/10/1016/j.jaad.2021.05.075.
PP-CIB-GBR-0059. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No